Although previous reviews and meta-analyses have provided insights into anti-PD-1/PD-L1 therapy in cancer, the efficacy of PD-1/PD-L1 inhibitors, in early-stage TNBC in particular, has never been systematically reviewed [19,20,21]. This evidence concerns the gene CD274 and cancer.